Thursday, August 28, 2014

Armetheon Finds $7M

Menlo Park-based Armetheon, a developer of biopharmceuticals aimed at treating cardiovascular conditions, has raised $7.0M in a first round of funding. The company said that the round was co-led by AshHill Biomedical Investments and Hercules Bioventures, and also included Atheneos Capital and biotech entrepreneur Larry Hsu (Impax Laboratories). The company is developing oral coagulants. More information »